Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Méry-Mignard

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Therapie|November 9, 2002
[Clinical trials in oncology: specific methodology problems]E Baumelou, D Méry-Mignard, J P Lehner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II studyP Rougier, D Lepille, J Bennouna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancerM Ducreux, M Ychou, J F Seitz, et al.
Bulletin Du Cancer|January 7, 2005
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patientsC Louvet, T André, E Gamelin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokineticsE Wasserman, C Cuvier, F Lokiec, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Therapie|November 9, 2002
[Clinical trials in oncology: specific methodology problems]E Baumelou, D Méry-Mignard, J P Lehner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II studyP Rougier, D Lepille, J Bennouna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancerM Ducreux, M Ychou, J F Seitz, et al.
Bulletin Du Cancer|January 7, 2005
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patientsC Louvet, T André, E Gamelin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokineticsE Wasserman, C Cuvier, F Lokiec, et al.
Pageof 1